Development of the First Ultra-Potent “Capsaicinoid” Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic Potential
Development of the First Ultra-Potent “Capsaicinoid” Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic Potential
[EN] TRPV1 AGONISTS, FORMULATIONS CONTAINING THEM AND USES THEREOF<br/>[FR] AGONISTES DE TRPV1, FORMULATIONS CONTENANT CES AGONISTES ET LEURS UTILISATIONS
申请人:INDENA SPA
公开号:WO2006010445A1
公开(公告)日:2006-02-02
The compounds of the general formula (I) in which X is represents two hydrogen atoms, a π-bond, oxygen or methylene; R2 is a C6-C12 aryl, or arylalkyl residue; R3 is hydrogen, 2-hydroxyethyl or 2-aminoethyl are useful for the treatment of pathologies mediated by vanilloid receptors type I.
TRPV1 AGONISTS, FORMULATIONS CONTAINING THEM AND USES THEREOF
申请人:INDENA S.p.A.
公开号:EP1773757A1
公开(公告)日:2007-04-18
ION CHANNEL ACTIVATORS AND METHODS OF USE
申请人:Flex Pharma, Inc.
公开号:EP3131541A1
公开(公告)日:2017-02-22
Trpv1 Agonists, Formulations Containing Them and Uses Thereof
申请人:Morazzoni Paolo
公开号:US20080132573A1
公开(公告)日:2008-06-05
The compounds of the general formula (I) in which X is represents two hydrogen atoms, a π-bond, oxygen or methylene: R2 is a C
6
-C
12
aryl, or arylalkyl residue: R3 is hydrogen, 2-hydroxyethyl or 2-aminoethyl are useful for the treatment of pathologies mediated by vanilloid receptors type I.